Adjuvant therapy of resected gastric cancer is necessary.


The currently reported 5-year survival rates for patients with resected stage II, IIIA, IIIB, and IV gastric cancer are 34%, 20%, 8%, and 7%, respectively. A subtotal or total gastrectomy with a D1 en bloc dissection of lymphatic tissue is the standard surgical treatment. Several meta-analyses of post-operative adjuvant trials have reported a significant benefit for chemotherapy-treated patients. Because most relapses occur locally, post-operative adjuvant chemoradiotherapy was studied in patients who received surgery alone or surgery followed by 5-fluorouracil and leucovorin (5-FU/LV, Mayo Clinic regimen) given before, after, and concurrently with radiotherapy in the Intergroup 0116 trial. The 3-year survival and 3-year disease-free survival rates were significantly higher in the adjuvant treatment group, making this regimen the adjuvant standard in the United States. A second trial, the MAGIC trial, also showed improved survival and disease-free survival with epirubicin, cisplatin, and 5-FU (ECF) given every 3 weeks pre- and post-operatively. Other agents in combination with perioperative radiotherapy and surgery are being investigated to treat patients with gastric cancer. New target-oriented agents, as well as tailored therapy based on the molecular profile of both the tumor and the patient, might also contribute to improved results.


Citations per Year

604 Citations

Semantic Scholar estimates that this publication has 604 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Carrato2005AdjuvantTO, title={Adjuvant therapy of resected gastric cancer is necessary.}, author={Alfredo Carrato and Javier Gallego-Plazas and C Guill{\'e}n-Ponce}, journal={Seminars in oncology}, year={2005}, volume={32 6 Suppl 9}, pages={S105-8} }